Expert Review of Clinical Immunology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

In-vitro assays for immuno-oncology drug efficacy assessment and screening for personalized cancer therapy: scopes and challenges
Expert Rev Clin Immunol. 2024 Apr 3:1-18. doi: 10.1080/1744666X.2024.2336583. Online ahead of print.ABSTRACTINTRODUCTION: Immunotherapies have revolutionized cancer treatment, but often fail to produce desirable therapeutic outcomes in all patients. Due to the inter-patient heterogeneity and complexity of the tumor microenvironment, personalized treatment approaches are gaining demand. Researchers have long been using a range of in-vitro assays including 2D models, organoid co-cultures, and cancer-on-a-chip platforms for cancer drug screening. A comparative analysis of these assays with their suitability, high-throughput c...
Source: Expert Review of Clinical Immunology - March 28, 2024 Category: Allergy & Immunology Authors: Md Marufur Rahman Greg Wells Juha K Rantala Thomas Helleday Munitta Muthana Sarah J Danson Source Type: research

In-vitro assays for immuno-oncology drug efficacy assessment and screening for personalized cancer therapy: scopes and challenges
Expert Rev Clin Immunol. 2024 Mar 28. doi: 10.1080/1744666X.2024.2336583. Online ahead of print.ABSTRACTINTRODUCTION: Immunotherapies have revolutionized cancer treatment, but often fail to produce desirable therapeutic outcomes in all patients. Due to the inter-patient heterogeneity and complexity of the tumor microenvironment, personalized treatment approaches are gaining demand. Researchers have long been using a range of in-vitro assays including 2D models, organoid co-cultures, and cancer-on-a-chip platforms for cancer drug screening. A comparative analysis of these assays with their suitability, high-throughput capac...
Source: Expert Review of Clinical Immunology - March 28, 2024 Category: Allergy & Immunology Authors: Marufur Rahman Greg Wells Juha K Rantala Thomas Helleday Munitta Muthana Sarah J Danson Source Type: research

Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma
We present a review of the most up-to-date literatureavailable on PubMed, focussing on studies from within the last 10 years. We also include data from ongoing and recent clinical trials targeting macrophages in melanoma listed on clinicaltrials.gov.EXPERT OPINION: Understanding the multifaceted role of macrophages in melanoma, including their interactions with immune and cancer cells, the influence of current therapies on macrophage phenotype and functions and how macrophages could be targeted with novel treatment approaches, are all critical for improving outcomes for patients with melanoma.PMID:38533720 | DOI:10.1080/17...
Source: Expert Review of Clinical Immunology - March 27, 2024 Category: Allergy & Immunology Authors: Shabana Habib Gabriel Osborn Zena Willsmore Min Waye Chew Sophie Jakubow Amanda Fitzpatrick Yin Wu Khushboo Sinha Hawys Lloyd-Hughes Jenny L C Geh Alastair D MacKenzie-Ross Sean Whittaker Victoria Sanz-Moreno Katie E Lacy Sophia N Karagiannis Rebecca Adam Source Type: research

Combination biologics or targeted synthetic disease-modifying anti-rheumatic drugs in the treatment of spondyloarthritis: a systematic literature review
CONCLUSIONS: There is not enough data to fully evaluate efficacy and safety of combination b/tsDMARDs in SpA treatment. Limited information shows apremilast plus bDMARD, or TNF inhibitor plus IL12/23 inhibitor combination to be efficacious and safe. Randomized controlled trials and larger cohort with a longer follow-up are required.PMID:38512065 | DOI:10.1080/1744666X.2024.2327589 (Source: Expert Review of Clinical Immunology)
Source: Expert Review of Clinical Immunology - March 21, 2024 Category: Allergy & Immunology Authors: Rand Abedalweli Michelle Nguyen Atul Deodhar Source Type: research

What is the relevance of FoxP3 in the tumor microenvironment and cancer outcomes?
Expert Rev Clin Immunol. 2024 Mar 25:1-7. doi: 10.1080/1744666X.2024.2334258. Online ahead of print.ABSTRACTINTRODUCTION: Forkhead box P3 (FoxP3) transcription factor plays critical roles in controlling immune responses and cancer progression in different cancers. FoxP3 expression within the tumor microenvironment (TME) may influence clinical outcomes negatively or positively, and it could play dual roles in cancer, either by promoting or inhibiting tumor development and progression. Some studies reported that high levels of FoxP3 could be associated with tumor progression and worse prognosis, while others reported contrad...
Source: Expert Review of Clinical Immunology - March 21, 2024 Category: Allergy & Immunology Authors: Abdo Meyiah Eyad Elkord Source Type: research